Drugs / Autologous CD34+ cells genetically modified
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03276455 | Sep 2017 → Sep 2020 | beta-thalassemia major | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD34+ cells genetically modified | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03276455 ↗ |
| Modality | Cell therapy | “autologous hematopoietic stem cell transduced with lentiviral vector” NCT03276455 ↗ |
| Route | Other | “The product will be injected intraosseously” NCT03276455 ↗ |
| Target | HBB | “encoding the therapeutic beta-globin gene” NCT03276455 ↗ |